The influence of etiological factors on immunoreactivity in patients with community-acquired pneumonia

Abstract

 The aim of this study was to uncover the characteristics of immunoreactivity in patients with community-acquired pneumonia, depending on the pathogen. The inflammatory process caused by various pathogens, has its own characteristics and affects the course of the disease. The study of the mechanisms of these complex interactions can improve the understanding of the processes occurring in community-acquired pneumonia, and, therefore, develop individual approaches to the therapy depending on the etiological factor.

Keywords

community-acquired pneumonia / etiological factor / immunoreactivity

References

[1] Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Инфекционная заболеваемость в Российской Федерации за январь-декабрь 2017 г. Доклад от 15.05.2018. Сведения об инфекционных и паразитарных заболеваниях за январь-декабрь 2017 г. [Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka. Infektsionnaya zabolevaemost’ v Rossijskoj Federatsii za yanvar’-dekabr’ 2017 g. Doklad ot 15.05.2018. Svedeniya ob infektsionnykh i parazitarnykh zabolevaniyakh za yanvar’-dekabr’ 2017 g. (In Russ).] Доступно по: http://rospotrebnadzor.ru/activities/statistical-materials/statictic_details.php?ELEMENT_ID=10049. Ссылка активна на 12.07.2018.

[2] Li Q, Li YX, Stahl GL, et al. Essential role of factor B of the alternative complement pathway in complement activation and opsonophagocytosis during acute pneumococcal otitis media in mice. Infect Immun. 2011;79(7):2578–2585. doi: 10.1128/IAI.00168-11.

[3] Thorburn AN, Brown AC, Nair PM, et al. Pneumococcal components induce regulatory T cells that attenuate the development of allergic airways disease by deviating and suppressing the immune response to allergen. J Immunol. 2013;191(8):4112–4120. doi: 10.4049/jimmunol.1201232.

[4] Terao Y, Mori Y, Yamaguchi M, et al. Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J Biol Chem. 2008;283(10):6253–6260. doi: 10.1074/jbc.M704821200.

[5] Garner AL, Fullagar JL, Day JA, et al. Development of a high-throughput screen and its use in the discovery of Streptococcus pneumoniae immunoglobulin A1 protease inhibitors. J Am Chem Soc. 2013;135(27):10014–10017. doi: 10.1021/ja404180x.

[6] Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol. 2008;3(6):635–648. doi: 10.2217/17460913.3.6.635.

[7] Itoh S, Hamada E., Kamoshida G, et al. Staphylococcal superantigen-like protein 10 (SSL10) binds to human immunoglobulin G (IgG) and inhibits complement activation via the classical pathway. Mol Immunol. 2010;47(4):932–938. doi: 10.1016/j.molimm.2009.09.027.

[8] Bestebroer J, Aerts PC, Rooijakkers SH, et al. Functional basis for complement evasion by staphylococcal superantigen-like 7. Cell Microbiol. 2010;12(10):1506–1516. doi: 10.1111/j.1462-5822.2010.01486.x.

[9] Postma B, Kleibeuker W, Poppelier MJ, et al. Residues 10–18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem. 2005;280(3):2020–2027. doi: 10.1074/jbc.M412230200.

[10] Potempa J, Pike RN. Corruption of innate immunity by bacterial proteases. J Innate Immun. 2009;1(2):70–87. doi: 10.1159/000181144.

[11] Laarman AJ, Ruyken M, Malone CL, et al. Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J Immunol. 2011;186(11):6445–6453. doi: 10.4049/jimmunol.1002948.

[12] Summah H, Qu JM. Biomarkers: a definite plus in pneumonia. Mediators Inflamm. 2009;2009:675753. doi: 10.1155/2009/675753.

[13] Guertler C, Wirz B, Christ-Crain M, et al. Inflammatory response predict long-term mortality risk in community-acquired pneumonia. Eur Respir J. 2011;37(6):1439–1446. doi: 10.1183/09031936.00121510.

[14] Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121(3):219–225. doi: 10.1016/j.amjmed.2007.10.033.

[15] Terai M, Honda T, Yamamoto S, et al. Early induction of interleukin-5 and peripheral eosinophilia in acute pneumonia in Japanese children infected by pandemic 2009 influenza A in the Tokyo area. Microbiol Immunol. 2011;55(5):341–346. doi: 10.1111/j.1348-0421.2011.00320.x.

[16] Choi IS, Byeon JH, Yoo Y, et al. Increased serum interleukin-5 and vascular endothelial growth factor in children with acute mycoplasma pneumonia and wheeze. Pediatr Pulmonol. 2009;44(5):423–428. doi: 10.1002/ppul.20961.

[17] Kraft M, Cassell GH, Henson JE, et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med. 1998;158(3):998–1001. doi: 10.1164/ajrccm.158.3.9711092.

[18] Waites KB, Talkington DF. Mycoplasma pneumonia and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697–728, table of contents. doi: 10.1128/CMR.17.4.697-728.2004.

[19] Sutherland RE, Olsen JS, McKinstry A, et al. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol. 2008;181(8):5598–5605. doi: 10.4049/jimmunol.181.8.5598.

[20] Padrones S, Garcia-Vidal C, Fernández-Serrano S, et.al. Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2010;29(10):1243—1251. doi: 10.1007/s10096-010-0993-0.

[21] Shapovalov KG, Belokrinitskaia TE, Burdinskaia ZhS, Maliarchikov AV. [Immunological and bacteriological monitoring of patients with pneumonia and influenza A/H1N1 infection. (Article in Russian).] Zh Mikrobiol Epidemiol Immunobiol. 2011;(1):79–82.

[22] [Zhang XL, Ji W, Ji ZH, et al. Epidemiological study on respiratory syncytial virus and its bronchopneumonia among children in Suzhou. (Article in Chinese).] Zhonghua Yu Fang Yi Xue Za Zhi. 2007;41(5):371–374.

[23] Mirsaeidi M, Peyrani P, Aliberti S, et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest. 2010;137(2):416–420. doi: 10.1378/chest.09-0998.

[24] Marshall AJ, Miles RJ, Richards L. The phagocytosis of mycoplasmas. J Med Microbiol. 1995;43(4):239–250. doi: 10.1099/00222615-43-4-239.

RIGHTS & PERMISSIONS

Rvacheva A.V., Pustovalov A.A., Zykov K.A.